Lexeo Therapeutics, Inc. Overview
LXEO market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
LXEO price chart · 1M
- O
- 2.83
- H
- 2.86
- L
- 2.71
- C
- 2.86
- Vol
- 27,270.00
Daily history from Nov 3, 2023
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $2.83
- Previous Close
- $2.90
- Day High
- $2.86
- Day Low
- $2.71
- 52 Week High
- $10.97
- 52 Week Low
- $2.55
- 7 Day Return
- -9.08%
- 30 Day Return
- -14.01%
- 90 Day Return
- -38.40%
- 1 Year Return
- -66.07%
- Daily Notional Volume
- $77.9K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.06 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.64 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -11,991.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.55 – $10.99 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $265.1M · P/B 2.94 · P/S 535.16.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
9 captured
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACMGlobenewswire Inc ·
Lexeo Therapeutics to Participate in the Chardan Healthcare ConferenceGlobenewswire Inc ·
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)Globenewswire Inc ·
8-K filing — Lexeo Therapeutics, Inc. (LXEO)SEC EDGAR ·